Wednesday, July 8, 2026

Patent intelligence · US

US 11767325

Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

granted A61PA61P25/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 35
Patent details — US 11767325

Quick answer

US 11767325 (Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators) is held by PRAXIS PRECISION MEDICINES, INC.. Status: granted. Granted Sep 26, 2023. Expires Sep 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
16
CPC classes
A61P, A61P25/00

More from PRAXIS PRECISION MEDICINES, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12404297

    Salts and crystal forms of GABA-A positive allosteric modulator

    PRAXIS PRECISION MEDICINES, INC. · Expires Aug 28, 2045

    granted
  2. US 12325711

    3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-α]pyrazine as an ion channel modulator

    PRAXIS PRECISION MEDICINES, INC. · Expires Jun 5, 2045

    granted
  3. US 12259378

    Dynamic clamps and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Expires Mar 20, 2045

    granted
  4. US 12145939

    Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

    PRAXIS PRECISION MEDICINES, INC. · Expires Nov 14, 2044

    granted
  5. US 12077502

    Formulations of T-type calcium channel modulators and methods of use thereof

    PRAXIS PRECISION MEDICINES, INC. · Expires Aug 29, 2044

    granted
  6. US 11918571

    Compounds and their methods of use

    PRAXIS PRECISION MEDICINES, INC. · Expires Feb 29, 2044

    granted
  7. US 11919836

    Prodrugs of fencamfamine

    Praxis Bioresearch, LLC · Expires Feb 29, 2044

    granted
  8. US 11866439

    Ion channel modulators

    PRAXIS PRECISION MEDICINES, INC. · Expires Jan 4, 2044

    granted

Frequently asked questions

What is US patent 11767325?

US 11767325 (Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators) is held by PRAXIS PRECISION MEDICINES, INC.. Status: granted. Granted Sep 26, 2023. Expires Sep 21, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11767325?

PRAXIS PRECISION MEDICINES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.

When does US 11767325 expire?

Our index shows an expiration date of Sep 21, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.